CNSP News and Press, CNS Pharmaceuticals Inc. From 09/26/23

Researchers from Boston Children’s Hospital say they have created a prototype surgical tool that can allow surgeons to remove pediatric brain tumors safely and in a less invasive manner.  The surgical robot uses hollow, nitinol robot arms to give surgeons the ability to switch tools...

CNS Pharmaceuticals is conducting a global clinical trial to evaluate its flagship drug candidate for treating glioblastoma, a deadly brain cancer CNS has enrolled 200 of its planned 243 patients for its clinical trial roster, and anticipates filling out the remainder of patients by year’...

Nottingham University researchers have devised a novel means of treating brain cancer that could signal a “ quantum leap” in brain-tumor treatments moving forward.  A multidisciplinary research team created a new way of targeting and eliminating cancer cells in typically hard-...

CNS Pharmaceuticals (NASDAQ: CNSP) , a clinical-stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, glioblastoma (“GBM”) and neuro-oncology, recently presented updated safety results from its potentially pivotal clinical stud...

Brigham and Women’s Hospital scientists have developed a microdevice to help researchers test the effectiveness of glioma treatments. Gliomas are a type of brain tumor that arise from glial cells in the spinal cord and brain before infiltrating surrounding brain cells. Because the ...

University of California Los Angeles (UCLA) scientists have published research findings that could provide deeper insight into why some types of brain tumors respond to immunotherapy while others don’t. While many types of brain tumors typically respond to immunotherapy, an aggressive ty...

CNS Pharmaceuticals recently announced updated results from its pivotal clinical study on GBM treatment through its lead drug candidate, Berubicin The novel anthracycline demonstrated its capability to be an innovative potential treatment option for GBM 151 patients have been enrolled in the ...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced enrollment of 200 of the expected 243 patients in the company’s ongoing potential...

Completion of enrollment of study on track by end of 2023 Topline data results from interim analysis also on track to announce by end of 2023 HOUSTON, TX / ACCESSWIRE / September 7, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company ...

A new analysis published in the “ JCO Oncology Practice ” journal has revealed that policies encouraging high-volume medical facilities may be harming cancer patients living in rural areas. Health policy researchers at the University of Pittsburg School of Public Health discove...